SCHEMBL1701293

SCHEMBL1701293

Cc1cccc(NC(c2cccc(O)c2)c2ccc3cccnc3c2O)n1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.81
SMN1; SMN2 Q16637 3/20 0.81
TP53 P04637 3/20 0.81
MDM2 Q00987 7/20 0.77
GAA P10253 2/20 0.67
LMNA P02545 3/20 0.65
KDM4E B2RXH2 2/20 0.65
MEN1 O00255 1/20 0.65
POLB P06746 1/20 0.65
MAPK1 P28482 1/20 0.65
HTT P42858 1/20 0.65
RAB9A P51151 1/20 0.65
KMT2A Q03164 1/20 0.65
TDP1 Q9NUW8 1/20 0.65
L3MBTL1 Q9Y468 1/20 0.65
ALDH1A1 P00352 1/20 0.63
TTR P02766 1/20 0.63
HPGD P15428 1/20 0.63
ALOX12 P18054 1/20 0.63
P4HB P07237 3/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18131752 1.00 MAPT (0.81) MAPTSMN1; SMN2TP53MDM2GAA
SCHEMBL18131664 1.00 MAPT (0.81) MAPTSMN1; SMN2TP53MDM2GAA
SCHEMBL14961226 0.92 MAPT (0.81) MAPTSMN1; SMN2TP53MDM2GAA
SCHEMBL18197735 0.90 TP53 (0.79) MAPTSMN1; SMN2TP53MDM2GAA
SCHEMBL15783135 0.90 MAPT (1.00) MAPTSMN1; SMN2TP53MDM2LMNA
SCHEMBL18131755 0.88 P4HB (0.82) MAPTSMN1; SMN2TP53MDM2LMNA
SCHEMBL20965575 0.88 P4HB (0.82) MAPTSMN1; SMN2TP53MDM2LMNA
SCHEMBL18131663 0.88 P4HB (0.82) MAPTSMN1; SMN2TP53MDM2LMNA
SCHEMBL15783076 0.87 GRK6 (0.77) MAPTSMN1; SMN2TP53MDM2GAA
SCHEMBL16508617 0.87 MAPT (0.74) MAPTSMN1; SMN2TP53MDM2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130131096-A1 8-HYDROXY-QUINOLINE DERIVATIVES UBICHEM KUTATO KORLATOLT FELELOSSEGU TARSASAG (HU) 2013-05-23 US claimed
EP-2566849-A1 8-HYDROXY-QUINOLINE DERIVATIVES "Avidin" Kutató, Fejleszt És Kereskedelmi Korlatolt Felelossegu Tarsasag (HU) 2013-03-13 EP claimed
WO-2011148208-A1 8-HYDROXY-QUINOLINE DERIVATIVES "AVIDIN" KUTATÓ, FEJLESZTŐ ÉS KERESKEDELMI KORLÁTOLT FELELŐSSÉGŰ TÁRSASÁG (HU) 2011-12-01 WO claimed
US-20190330188-A1 ENANTIOMERS OF 8-HYDROXYQUINOLINE DERIVATIVES AND THE SYNTHESIS THEREOF AVIDIN CO. LTD (HU) 2019-10-31 US disclosed
EP-2566849-B1 8-HYDROXY-QUINOLINE DERIVATIVES AVIDIN KUTATO FEJLESZTOE ES KERESKEDELMI KORLATOLT FELELOESSEGUE TARSASAG (HU) 2019-09-18 EP disclosed
EP-2566849-B1 8-HYDROXY-QUINOLINE DERIVATIVES AVIDIN KUTATO FEJLESZTOE ES KERESKEDELMI KORLATOLT FELELOESSEGUE TARSASAG (HU) 2019-09-18 EP disclosed
US-10287265-B2 Enantiomers of 8-hydroxyquinoline derivatives and the synthesis thereof AVIDIN CO. LTD. (HU) 2019-05-14 US disclosed
US-8871937-B2 8-hydroxy-quinoline derivatives “AVIDIN” Kutato, Fejleszto es Kereskedelmi Korlatolt Felelossegu Tarsasag (HU) 2014-10-28 US disclosed
US-8871937-B2 8-hydroxy-quinoline derivatives “AVIDIN” Kutato, Fejleszto es Kereskedelmi Korlatolt Felelossegu Tarsasag (HU) 2014-10-28 US disclosed
US-8871937-B2 8-hydroxy-quinoline derivatives “AVIDIN” Kutato, Fejleszto es Kereskedelmi Korlatolt Felelossegu Tarsasag (HU) 2014-10-28 US disclosed
US-20130131096-A1 8-HYDROXY-QUINOLINE DERIVATIVES UBICHEM KUTATO KORLATOLT FELELOSSEGU TARSASAG (HU) 2013-05-23 US disclosed
US-20130131096-A1 8-HYDROXY-QUINOLINE DERIVATIVES UBICHEM KUTATO KORLATOLT FELELOSSEGU TARSASAG (HU) 2013-05-23 US disclosed
US-20130131096-A1 8-HYDROXY-QUINOLINE DERIVATIVES UBICHEM KUTATO KORLATOLT FELELOSSEGU TARSASAG (HU) 2013-05-23 US disclosed
EP-2566849-A1 8-HYDROXY-QUINOLINE DERIVATIVES "Avidin" Kutató, Fejleszt És Kereskedelmi Korlatolt Felelossegu Tarsasag (HU) 2013-03-13 EP disclosed
WO-2011148208-A1 8-HYDROXY-QUINOLINE DERIVATIVES "AVIDIN" KUTATÓ, FEJLESZTŐ ÉS KERESKEDELMI KORLÁTOLT FELELŐSSÉGŰ TÁRSASÁG (HU) 2011-12-01 WO disclosed
WO-2011148208-A1 8-HYDROXY-QUINOLINE DERIVATIVES "AVIDIN" KUTATÓ, FEJLESZTŐ ÉS KERESKEDELMI KORLÁTOLT FELELŐSSÉGŰ TÁRSASÁG (HU) 2011-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10287265-B2 Enantiomers of 8-hydroxyquinoline derivatives and the synthesis thereof TPH1, HTR5A, TPH2 MAPT 3429/4885SMN1; SMN2 1255/4885TP53 4452/4885
US-20190330188-A1 ENANTIOMERS OF 8-HYDROXYQUINOLINE DERIVATIVES AND THE SYNTHESIS THEREOF TPH1, TPH2, HTR5A MAPT 2690/4885SMN1; SMN2 677/4885TP53 3980/4885
US-20130131096-A1 8-HYDROXY-QUINOLINE DERIVATIVES CYP2C8, NQO1, KEAP1 MAPT 2319/4885SMN1; SMN2 1845/4885TP53 4173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.